CymaBay Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview

CymaBay Therapeutics

04/11/2023 03:04

* CymaBay Therapeutics Inc  CBAY.OQ   CBAY.O  is expected
to show
a rise in quarterly revenue when it reports  results 
    * The Newark California California-based  company is
expected to
report revenue of $427.27 thousand, according to the mean
estimate from 11 analysts, based on LSEG data.  
    * ​Refinitiv's mean analyst estimate for CymaBay
Therapeutics Inc
is for a loss of 30 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for CymaBay
Therapeutics Inc is $22​, above​ its last closing price
of $16.36. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.20       -0.20      -0.01     Beat    95.1
 Mar. 31 2023  -0.11       -0.09      -0.29     Missed  -230.4
 Dec. 31 2022  -0.30       -0.30      -0.30     Met     0​
 Sep. 30 2022  -0.30       -0.30      -0.28     Beat    7
 ​​Jun.        -0.30       -0.30      -0.31     Missed  -3.8
 30 2022                                                
 Mar. 31 2022  -0.31       -0.31      -0.32     Missed  -3.3​
 Dec. 31 2021              -0.26      -0.34     Missed  -30.1
 Sep. 30 2021  -0.28       -0.26      -0.33     Missed  -25.4
 This summary was machine generated November 4 at 03:04 GMT.  All
figures in US dollars  unless otherwise stated